Haruki Yamada

Haruki Yamada


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
WXWencheng Xu
Wencheng Xu
SCShuhe Chen
Shuhe Chen
XWXiaoqin Wang
Xiaoqin Wang
STSachiko Tanaka
Sachiko Tanaka
KOKenji Onda
Kenji Onda
俊平俊 彦 平野
俊 彦 平野

1 July 2017 in European Journal of Pharmacology
Verified
Journal Article
Closed access
WXWencheng Xu
Wencheng Xu
KMKehan Meng
Kehan Meng
YTYuanchao Tu
Yuanchao Tu
STSachiko Tanaka
Sachiko Tanaka
KOKenji Onda
Kenji Onda
HYHaruki Yamada
Haruki Yamada

10 August 2017 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
WXWencheng Xu
Wencheng Xu
KMKehan Meng
Kehan Meng
JKJunichi Kusano
Junichi Kusano
HMHiroto Matsuda
Hiroto Matsuda
YHYoshikazu Hara
Yoshikazu Hara
俊平俊 彦 平野
俊 彦 平野

11 May 2024 in BMC Complementary Medicine and Therapies
Verified
Journal Article
Open access
PDF file
WXWencheng Xu
Wencheng Xu
SCShuhe Chen
Shuhe Chen
XWXiaoqin Wang
Xiaoqin Wang
JMJinwen Min
Jinwen Min
STSachiko Tanaka
Sachiko Tanaka
俊平俊 彦 平野
俊 彦 平野
Background: Cepharanthin® alone or in combination with glucocorticoid (GC) has been used to treat chronic immune thrombocytopenia (ITP) since the 1990s. Cepharanthine (CEP) is one of the main active components of Cepharanthin®. The purpose of this study was to investigate the effects of CEP on GC pharmacodynamics on immune cells and analyse the possible action mechanism of their interactions. Methods: Peripheral blood mononuclear cells (PBMCs), T lymphocytic leukemia MOLT-4 cells and daunorubicin resistant MOLT-4 cells (MOLT-4/DNR) were used to evaluate the pharmacodynamics and molecular mechanisms. Drug pharmacodynamics was evaluated by WST-8 assay. P-glycoprotein function was examined by rhodamine 123 assay. CD4+CD25+Foxp3+ regulatory T cells and Th1/Th2/Th17 cytokines were detected by flow cytometry. P-glycoprotein expression and GC receptor translocation were examined by Western blot. Results: CEP synergistically increased methylprednisolone (MP) efficacy with the suppressive effect on the cell viability of PBMCs. 0.3 and 1 μM of CEP significantly inhibited P-glycoprotein efflux function of CD4+ cells, CD8+ cells, and lymphocytes (P<0.05). 0.03~3 μM of CEP also inhibited the P-glycoprotein efflux function in MOLT-4/DNR cells in a concentration-dependent manner (P<0.001). However, 0.03~3 μM of CEP did not influence P-glycoprotein expression. 0.03~0.3 μM of CEP significantly increased the GC receptor distribution from the cytoplasm to the nucleus in a concentration-dependent manner in MOLT-4/DNR cells. The combination did not influence the frequency of CD4+, CD4+CD25+ and CD4+CD25+Foxp3+ T cells or the secretion of Th1/Th2/Th17 cytokines from PBMCs. In contrast, CEP alone at 1 μM decreased the percentage of CD4+ T cell significantly (P<0.01). It also inhibited the secretion of IL-6, IL-10, IL-17, TNF-α, and IFN-γ. Conclusions: CEP synergistically promoted MP pharmacodynamics to decrease the cell viability of the mitogen-activated PBMCs, possibly via inhibiting P-glycoprotein function and potentiating GC receptor translocation. The present study provides new evidence of the therapeutic effect of Cepharanthin® alone or in combination with GC for the management of chronic ITP.

14 July 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
NBNatalie K. Binder
Natalie K. Binder
KOKenji Onda
Kenji Onda
SBSally Beard
Sally Beard
KUKei Uchiyama
Kei Uchiyama
COChika Ohi
Chika Ohi
NHNatalie J. Hannan
Natalie J. Hannan
Preeclampsia is a serious pregnancy complication characterised by maternal vascular dysfunction, placental dysfunction, and organ injury, with no effective treatment currently available. Kampo, a system of Japanese traditional medicine comprising standardised herbal formulations, could target pathophysiological pathways driving preeclampsia. We evaluated the effects of select Kampo formulations on markers of preeclampsia using primary human trophoblasts, placental explants, human umbilical vein endothelial cells (HUVECs), and uterine microvascular endothelial cells (UtMVECs). Twelve formulations were initially screened in HUVECs, and six formulations advanced for further study. TNFα was used to induce endothelial dysfunction, and angiogenic, antioxidant, inflammatory, and vascular dysfunction markers were assessed. Overall, Kampo formulations had minimal effect on sFlt-1 expression and only modest effects on sFlt-1 secretion by primary human trophoblast. In contrast, several formulations consistently increased placental growth factor (PlGF) expression and secretion, upregulated HMOX1 in trophoblasts, and enhanced PlGF secretion from placental explants. In endothelial cells, Kampo treatment partially reversed TNFα-induced dysfunction, demonstrated by reduced VCAM1 expression, and additional endothelial cell type-dependent effects on ET-1 and inflammatory pathways. These findings indicate that selected Kampo formulations modulate key pathways involved in the pathophysiology underpinning preeclampsia and warrant further investigation as potential therapeutic candidates.